Work status.

Work status.</p

Cardiovascular risk profile.

Cardiovascular risk profile.</p

SF-36 scale scores (estimated marginal means) for men and women with inflammatory arthritis (adjusted for age and diagnosis) and for men and women from the general Norwegian population (adjusted for age).

SF-36 scale scores (estimated marginal means) for men and women with inflammatory arthritis (adjusted for age and diagnosis) and for men and women from the general Norwegian population (adjusted for age).</p

Demographics.

Demographics.</p

Comparison of disease activity measures, physical functioning, health-related quality of life and laboratory markers between men and women with inflammatory arthritis.

Comparison of disease activity measures, physical functioning, health-related quality of life and laboratory markers between men and women with inflammatory arthritis.</p

Additional file 1 of Changes of inflammation in patients with psoriatic arthritis after high intensity interval training assessed by ultrasound and MRI, a randomized controlled trial

Additional file 1: Figure S1. Changes in US B-mode and power doppler scores of the joints for each individual in the control and HIIT groups at baseline and 3 months

Additional file 1: of Effect of filgotinib, a selective JAK 1 inhibitor, with and without methotrexate in patients with rheumatoid arthritis: patient-reported outcomes

Figure S1. Patient disposition during the methotrexate (MTX) add-on study (A) and the monotherapy study (B). (ZIP 1513 kb

Additional file 7: of Effect of filgotinib, a selective JAK 1 inhibitor, with and without methotrexate in patients with rheumatoid arthritis: patient-reported outcomes

Figure S4. Proportion of subjects achieving normative SF-36 PCS and MCS scores (≥50) at week 12 according to ACR20 responder status. A PCS, MTX add-on, B PCS, monotherapy, C MCS, MTX add-on, D MCS, monotherapy. (EPS 2249 kb

Additional file 6: of Effect of filgotinib, a selective JAK 1 inhibitor, with and without methotrexate in patients with rheumatoid arthritis: patient-reported outcomes

Figure S3. Proportion of subjects achieving normative FACIT-Fatigue score (≥40) at week 12 according to ACR20 responder status in the MTX add-on study (A) and monotherapy study (B). (EPS 1984 kb

Additional file 2: of Effect of filgotinib, a selective JAK 1 inhibitor, with and without methotrexate in patients with rheumatoid arthritis: patient-reported outcomes

Document 1. List of ethical bodies that approved the DARWIN 1 study for each of the 106 study centers. (PDF 129 kb